Avaliação dos biomarcadores ngal, cistatina C e IL-18 no sangue e urina de pacientes sépticos com e sem lesão renal aguda.

Detalhes bibliográficos
Autor(a) principal: Caltabiano, Regina Helena Lima [UNIFESP]
Data de Publicação: 2018
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=6416069
https://repositorio.unifesp.br/handle/11600/53151
Resumo: Sepsis has long been recognized as a foremost precipitant of acute kidney injury (AKI) in critically ill patients treated in Intensive Care Units (ICU), with poor outcomes, high mortality and longer hospitalization time. The later diagnosis of AKI based on serum creatinine changes and urine output is an important point to this poor outcome. Biomarkers have been showing to be an effective method to detect early AKI, to predict the progression of AKI, and the need of renal replacement therapy (RRT) in critically ill patients, guiding a preventive treatment and early dialysis, for more positive outcome. Objectives: Evaluate how Neutrophil gelatinase-associated lipocalin (NGAL) plasma(p) and urinary(u); Cystatin C plasma; and Interleukin-18 urinary (IL- 18u) react due to different classifications of AKI, AKI diagnosis, need to perform renal replacement therapy and mortality in critically ill patients in ICU with severe sepsis and septic shock. Methods: Prospective cohort, 40 patients that were in the ICU were recruited, 11 were diagnosed with severe sepsis, and 29 with septic shock, based on the consensus definition from 1992. AKI classification was used RIFLE and AKIN daily since enrollment in the study. To detect biomarkers ELISA method was used. Results: To differentiate patients with and without kidney injury by AKIN classification on the day of enrollment in the study, the biomarkers showed the following results: NGALp - Odds Ratio (OR) 5,6 (p=0,055) and AUROC 0,70, NAGLu - OR 11,9 (p=0,03) and AUROC 0,73, Cystatin C plasma - OR 6,86 (p=0,089) and AUROC 0,67, IL-18 urinary - OR 8,73 (p=0,059) and AUROC 0,72; by RIFLE diuresis classification on the day of enrollment in the study: NGALp - OR 3,5 (p=0,118), NGALu - OR 28 (p=0,001) and AUROC 0,82, Cystatin C plasma - OR 6,0 (p=0,028) and AUROC 0,57, IL-18u - OR 5,4 (p= 0,058) and AUROC 0,71; by RIFLE of creatinine classification on the day of enrollment in the study: NGALp – OR 3,61 (p=0,080) and AUROC 0,65, NGALu - OR 4,06 (p=0,059) and AUROC 0,60, Cystatin C plasma - OR13 (p=0,022) and AUROC 0,72, IL18u - OR 2,33 (p=0,242) and AUROC 0,51. When analyzing hemodialysis prediction on the day of enrollment in the study, the biomarkers showed the following results: NGALp OR 11,9 (p=0,03) and AUROC 0,69, NGALu OR 36 (p=0,001) and AUROC 0,81, Cystatin C OR 24 (p=0,002) and AUROC 0,80, IL-18u OR 6,38 (p=0,045) and AUROC 0,74. When analyzing hemodialysis prediction after 24 hours of pacient enrollment: NGALp OR 15,75 and AUROC 0,80, NGALu AUROC 0,90, Cystatin C OR 5,5 (p=0,056) and AUROC 0,70, IL-18u OR 14 (p=0,029) and AUROC 0,76. Related outcomes prediction only NGALp 24 hours of patient enrollment showed significant AUROC 0,72 to mortality. Conclusion: the three biomarkers investigated in the study NGAL plasma and urinary, Cystatin C plasma, and IL-18 urinary, showed to be able to differentiate patients with sepsis with and without AKI and showed to be an effective method to predict hemodialysis in this population with sepsis. The only biomarker associate with mortality was NGALp after 24 hours of patient enrollment.
id UFSP_f063b3e9bded64c81a21adcc8e475f8e
oai_identifier_str oai:repositorio.unifesp.br/:11600/53151
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Avaliação dos biomarcadores ngal, cistatina C e IL-18 no sangue e urina de pacientes sépticos com e sem lesão renal aguda.SepseLesão renal agudaLipocalinaInterleucina- 1 5 cistatina CSepseLesão renal agudaLipocalinaInterleucina- 1 5 cistatina CSepsis has long been recognized as a foremost precipitant of acute kidney injury (AKI) in critically ill patients treated in Intensive Care Units (ICU), with poor outcomes, high mortality and longer hospitalization time. The later diagnosis of AKI based on serum creatinine changes and urine output is an important point to this poor outcome. Biomarkers have been showing to be an effective method to detect early AKI, to predict the progression of AKI, and the need of renal replacement therapy (RRT) in critically ill patients, guiding a preventive treatment and early dialysis, for more positive outcome. Objectives: Evaluate how Neutrophil gelatinase-associated lipocalin (NGAL) plasma(p) and urinary(u); Cystatin C plasma; and Interleukin-18 urinary (IL- 18u) react due to different classifications of AKI, AKI diagnosis, need to perform renal replacement therapy and mortality in critically ill patients in ICU with severe sepsis and septic shock. Methods: Prospective cohort, 40 patients that were in the ICU were recruited, 11 were diagnosed with severe sepsis, and 29 with septic shock, based on the consensus definition from 1992. AKI classification was used RIFLE and AKIN daily since enrollment in the study. To detect biomarkers ELISA method was used. Results: To differentiate patients with and without kidney injury by AKIN classification on the day of enrollment in the study, the biomarkers showed the following results: NGALp - Odds Ratio (OR) 5,6 (p=0,055) and AUROC 0,70, NAGLu - OR 11,9 (p=0,03) and AUROC 0,73, Cystatin C plasma - OR 6,86 (p=0,089) and AUROC 0,67, IL-18 urinary - OR 8,73 (p=0,059) and AUROC 0,72; by RIFLE diuresis classification on the day of enrollment in the study: NGALp - OR 3,5 (p=0,118), NGALu - OR 28 (p=0,001) and AUROC 0,82, Cystatin C plasma - OR 6,0 (p=0,028) and AUROC 0,57, IL-18u - OR 5,4 (p= 0,058) and AUROC 0,71; by RIFLE of creatinine classification on the day of enrollment in the study: NGALp – OR 3,61 (p=0,080) and AUROC 0,65, NGALu - OR 4,06 (p=0,059) and AUROC 0,60, Cystatin C plasma - OR13 (p=0,022) and AUROC 0,72, IL18u - OR 2,33 (p=0,242) and AUROC 0,51. When analyzing hemodialysis prediction on the day of enrollment in the study, the biomarkers showed the following results: NGALp OR 11,9 (p=0,03) and AUROC 0,69, NGALu OR 36 (p=0,001) and AUROC 0,81, Cystatin C OR 24 (p=0,002) and AUROC 0,80, IL-18u OR 6,38 (p=0,045) and AUROC 0,74. When analyzing hemodialysis prediction after 24 hours of pacient enrollment: NGALp OR 15,75 and AUROC 0,80, NGALu AUROC 0,90, Cystatin C OR 5,5 (p=0,056) and AUROC 0,70, IL-18u OR 14 (p=0,029) and AUROC 0,76. Related outcomes prediction only NGALp 24 hours of patient enrollment showed significant AUROC 0,72 to mortality. Conclusion: the three biomarkers investigated in the study NGAL plasma and urinary, Cystatin C plasma, and IL-18 urinary, showed to be able to differentiate patients with sepsis with and without AKI and showed to be an effective method to predict hemodialysis in this population with sepsis. The only biomarker associate with mortality was NGALp after 24 hours of patient enrollment.Sepse é uma das principais causas de lesão renal aguda em unidade de terapia intensiva com alta taxa de mortalidade e tempo de internação. O diagnóstico tardio da lesão renal aguda (LRA) por meio do uso de creatinina sérica e débito urinário é um importante fator que contribui para esse desfecho desfavorável. Com isso, a necessidade de se utilizar biomarcadores que auxiliam no diagnóstico precoce, na predição de pacientes que evoluirão de uma maneira mais grave com necessidade de hemodiálise, se faz necessário para instituir medidas de prevenção, cuidados clínicos e tratamento dialítico de uma maneira mais precisa e precoce, que resulte em melhores desfechos clínicos. Objetivos: Avaliar o comportamento dos biomarcadores Neutrophil gelatinase-associated lipocalin (NGAL) plasmático(p) e urinário(u), Cistatina C plasmática e Interleucina-18 urinária (IL-18u) frente às diversas classificações de LRA, diagnóstico de LRA, necessidade de realizar terapia de substituição renal e mortalidade em pacientes internados em unidade de terapia intensiva com diagnóstico de sepse grave e choque séptico. Método: Coorte prospectiva, incluídos 40 pacientes, classificados de acordo com as definições do consenso de sepse de 1992 sendo 11 com sepse grave e 29 com choque séptico. Para classificar LRA foi utilizado critério de RIFLE e AKIN diariamente a partir do momento da inclusão no estudo. Detecção dos biomarcadores foi feita pelo método de ELISA. Resultados: Para diferenciar pacientes com e sem lesão pela classificação de AKIN no dia da inclusão do estudo, os biomarcadores mostraram os seguintes resultados: NGALp - Odds Ratio (OR) 5,6 (p=0,055) e AUROC 0,70, NAGLu - OR 11,9 (p=0,03) e AUROC 0,73, Cistatina C plasmática - OR 6,86 (p=0,089) e AUROC 0,67, IL-18 urinária - OR 8,73 (p=0,059) e AUROC 0,72; pela classificação de RIFLE de diurese no dia da inclusão do estudo: NGALp - OR 3,5 (p=0,118), NGALu - OR 28 (p=0,001) e AUROC 0,82, Cistatina C plasmática - OR 6,0 (p=0,028) e AUROC 0,57, IL-18u - OR 5,4 (p= 0,058) e AUROC 0,71; pela classificação de RIFLE de creatinina no dia da inclusão do estudo NGALp – OR 3,61 (p=0,080) e AUROC 0,65, NGALu - OR 4,06 (p=0,059) e AUROC 0,60, Cistatina C plasmática - OR13 (p=0,022) e AUROC 0,72, IL18u - OR 2,33 (p=0,242) e AUROC 0,51. Ao analisar predição de hemodiálise no dia da inclusão do estudo, os biomarcadores mostraram os seguintes resultados: NGALp OR 11,9 (p=0,03) e AUROC 0,69, NGALu OR 36 (p=0,001) e AUROC 0,81, Cistatina C OR 24 (p=0,002) e AUROC 0,80, IL18 OR 6,38 (p=0,045) e AUROC 0,74. Ao analisar predição de hemodiálise 24 horas após inclusão no estudo NGALp OR 15,75 e AUROC 0,80, NGALu AUROC 0,90, Cistatina C OR 5,5 (p=0,056) e AUROC 0,70, IL18 OR 14 (p=0,029) e AUROC 0,76. Em relação à predição do desfecho mortalidade somente o NGALp 24 horas após inclusão no estudo mostrou AUROC 0,72. Conclusão: Os três biomarcadores estudados, NGAL plasmático e urinário, Cistatina C plasmática e IL-18 urinário, foram capazes de diferenciar pacientes sépticos com e sem LRA e de predizer hemodiálise nesta população séptica. Somente o NGALp 24 horas mostrou associação com mortalidade.Dados abertos - Sucupira - Teses e dissertações (2018)Universidade Federal de São Paulo (UNIFESP)Salomao, Reinaldo [UNIFESP]http://lattes.cnpq.br/8370334857007434http://lattes.cnpq.br/9018522211856082Caltabiano, Regina Helena Lima [UNIFESP]2020-03-25T12:11:02Z2020-03-25T12:11:02Z2018-07-24info:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/publishedVersion60 f.application/pdfhttps://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=64160692018-1096.pdfhttps://repositorio.unifesp.br/handle/11600/53151porinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-02T20:49:17Zoai:repositorio.unifesp.br/:11600/53151Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-02T20:49:17Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Avaliação dos biomarcadores ngal, cistatina C e IL-18 no sangue e urina de pacientes sépticos com e sem lesão renal aguda.
title Avaliação dos biomarcadores ngal, cistatina C e IL-18 no sangue e urina de pacientes sépticos com e sem lesão renal aguda.
spellingShingle Avaliação dos biomarcadores ngal, cistatina C e IL-18 no sangue e urina de pacientes sépticos com e sem lesão renal aguda.
Caltabiano, Regina Helena Lima [UNIFESP]
Sepse
Lesão renal aguda
Lipocalina
Interleucina- 1 5 cistatina C
Sepse
Lesão renal aguda
Lipocalina
Interleucina- 1 5 cistatina C
title_short Avaliação dos biomarcadores ngal, cistatina C e IL-18 no sangue e urina de pacientes sépticos com e sem lesão renal aguda.
title_full Avaliação dos biomarcadores ngal, cistatina C e IL-18 no sangue e urina de pacientes sépticos com e sem lesão renal aguda.
title_fullStr Avaliação dos biomarcadores ngal, cistatina C e IL-18 no sangue e urina de pacientes sépticos com e sem lesão renal aguda.
title_full_unstemmed Avaliação dos biomarcadores ngal, cistatina C e IL-18 no sangue e urina de pacientes sépticos com e sem lesão renal aguda.
title_sort Avaliação dos biomarcadores ngal, cistatina C e IL-18 no sangue e urina de pacientes sépticos com e sem lesão renal aguda.
author Caltabiano, Regina Helena Lima [UNIFESP]
author_facet Caltabiano, Regina Helena Lima [UNIFESP]
author_role author
dc.contributor.none.fl_str_mv Salomao, Reinaldo [UNIFESP]
http://lattes.cnpq.br/8370334857007434
http://lattes.cnpq.br/9018522211856082
dc.contributor.author.fl_str_mv Caltabiano, Regina Helena Lima [UNIFESP]
dc.subject.por.fl_str_mv Sepse
Lesão renal aguda
Lipocalina
Interleucina- 1 5 cistatina C
Sepse
Lesão renal aguda
Lipocalina
Interleucina- 1 5 cistatina C
topic Sepse
Lesão renal aguda
Lipocalina
Interleucina- 1 5 cistatina C
Sepse
Lesão renal aguda
Lipocalina
Interleucina- 1 5 cistatina C
description Sepsis has long been recognized as a foremost precipitant of acute kidney injury (AKI) in critically ill patients treated in Intensive Care Units (ICU), with poor outcomes, high mortality and longer hospitalization time. The later diagnosis of AKI based on serum creatinine changes and urine output is an important point to this poor outcome. Biomarkers have been showing to be an effective method to detect early AKI, to predict the progression of AKI, and the need of renal replacement therapy (RRT) in critically ill patients, guiding a preventive treatment and early dialysis, for more positive outcome. Objectives: Evaluate how Neutrophil gelatinase-associated lipocalin (NGAL) plasma(p) and urinary(u); Cystatin C plasma; and Interleukin-18 urinary (IL- 18u) react due to different classifications of AKI, AKI diagnosis, need to perform renal replacement therapy and mortality in critically ill patients in ICU with severe sepsis and septic shock. Methods: Prospective cohort, 40 patients that were in the ICU were recruited, 11 were diagnosed with severe sepsis, and 29 with septic shock, based on the consensus definition from 1992. AKI classification was used RIFLE and AKIN daily since enrollment in the study. To detect biomarkers ELISA method was used. Results: To differentiate patients with and without kidney injury by AKIN classification on the day of enrollment in the study, the biomarkers showed the following results: NGALp - Odds Ratio (OR) 5,6 (p=0,055) and AUROC 0,70, NAGLu - OR 11,9 (p=0,03) and AUROC 0,73, Cystatin C plasma - OR 6,86 (p=0,089) and AUROC 0,67, IL-18 urinary - OR 8,73 (p=0,059) and AUROC 0,72; by RIFLE diuresis classification on the day of enrollment in the study: NGALp - OR 3,5 (p=0,118), NGALu - OR 28 (p=0,001) and AUROC 0,82, Cystatin C plasma - OR 6,0 (p=0,028) and AUROC 0,57, IL-18u - OR 5,4 (p= 0,058) and AUROC 0,71; by RIFLE of creatinine classification on the day of enrollment in the study: NGALp – OR 3,61 (p=0,080) and AUROC 0,65, NGALu - OR 4,06 (p=0,059) and AUROC 0,60, Cystatin C plasma - OR13 (p=0,022) and AUROC 0,72, IL18u - OR 2,33 (p=0,242) and AUROC 0,51. When analyzing hemodialysis prediction on the day of enrollment in the study, the biomarkers showed the following results: NGALp OR 11,9 (p=0,03) and AUROC 0,69, NGALu OR 36 (p=0,001) and AUROC 0,81, Cystatin C OR 24 (p=0,002) and AUROC 0,80, IL-18u OR 6,38 (p=0,045) and AUROC 0,74. When analyzing hemodialysis prediction after 24 hours of pacient enrollment: NGALp OR 15,75 and AUROC 0,80, NGALu AUROC 0,90, Cystatin C OR 5,5 (p=0,056) and AUROC 0,70, IL-18u OR 14 (p=0,029) and AUROC 0,76. Related outcomes prediction only NGALp 24 hours of patient enrollment showed significant AUROC 0,72 to mortality. Conclusion: the three biomarkers investigated in the study NGAL plasma and urinary, Cystatin C plasma, and IL-18 urinary, showed to be able to differentiate patients with sepsis with and without AKI and showed to be an effective method to predict hemodialysis in this population with sepsis. The only biomarker associate with mortality was NGALp after 24 hours of patient enrollment.
publishDate 2018
dc.date.none.fl_str_mv 2018-07-24
2020-03-25T12:11:02Z
2020-03-25T12:11:02Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=6416069
2018-1096.pdf
https://repositorio.unifesp.br/handle/11600/53151
url https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=6416069
https://repositorio.unifesp.br/handle/11600/53151
identifier_str_mv 2018-1096.pdf
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 60 f.
application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
publisher.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268326554107904